Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 55 peer-reviewed journal articles Updated
Dermatology

Epidermolysis bullosa acquisita: A Patient Guide

At a Glance

EBA is a rare autoimmune disease in which antibodies attack type VII collagen, causing fragile blisters and sometimes scarring of the mouth, eyes, or throat. Diagnosis combines a skin biopsy with specialized immune tests, and treatment focuses on skin protection plus specialist-directed medicines.

Epidermolysis bullosa acquisita (EBA) is a rare, acquired autoimmune condition that affects the skin and, in many cases, the delicate linings of the mouth, eyes, and throat. Unlike inherited forms of epidermolysis bullosa that are present from birth, EBA typically appears in adulthood when the immune system mistakenly begins attacking a specific protein called Type VII collagen [1]. This protein is the primary component of anchoring fibrils, which act like a biological velcro that secures the top layer of skin (the epidermis) to the layer beneath it (the dermis). When these fibrils are damaged by autoantibodies, the skin lose its structural integrity, leading to the formation of fragile blisters [2][3].

The way EBA behaves can vary significantly between individuals, generally falling into two main clinical patterns. The mechanobullous form is characterized by extreme skin fragility, where minor friction or trauma—such as the rubbing of shoes or a gentle bump—causes blisters to form on the hands, feet, elbows, and knees [4]. These blisters often heal with scarring and small white bumps called milia. In contrast, the inflammatory form can look very different, featuring widespread, itchy blisters that may resemble other conditions like bullous pemphigoid [3][5]. Regardless of the form, an accurate diagnosis is essential and requires specialized tests, including direct immunofluorescence (DIF) to look for a specific “u-serrated” pattern in the skin and blood tests like ELISA to check for collagen antibodies [6][7]. While these tests strongly support the diagnosis, negative serology does not entirely exclude it, and results require careful clinical and histologic correlation.

Living with EBA requires a shift toward constant skin protection and careful monitoring for high-risk complications. Beyond the skin, EBA can affect the mucous membranes, where it poses a risk of permanent scarring that can lead to vision loss, difficulty swallowing, or breathing issues [8][9]. Because of these risks, care is best managed by a multidisciplinary team, with a low-threshold for baseline assessments by experts in dermatology, ophthalmology, and gastroenterology [10]. Practical daily management focuses on trauma avoidance—using soft fabrics, padded footwear, and non-adherent dressings—to minimize the mechanical forces that trigger new blisters [11].

While EBA is a chronic and often challenging condition to treat, it is a journey that is managed in stages. Treatment is tailored to the severity of your symptoms and phenotype, and may range from anti-inflammatory medications like dapsone to advanced, specialist-directed systemic therapies like rituximab or IVIG for more severe disease [12][13]. Remission is a long-term goal that requires patience, often taking many months of consistent care to achieve [14]. By working closely with a specialized care team and focusing on protective skin habits, you can take an active role in managing the condition and maintaining your quality of life.

In this guide

6 chapters

01

Understanding Epidermolysis Bullosa Acquisita (EBA)

Learn what epidermolysis bullosa acquisita (EBA) is, how it differs from inherited EB, how doctors diagnose it, and which symptoms and variants to know.

02

Symptoms and Patterns of EBA

Learn how epidermolysis bullosa acquisita (EBA) symptoms differ by pattern, including skin fragility, itching, scarring, mucosal disease, and warning signs.

03

Understanding Your Diagnosis and Pathology Reports

Learn how EBA pathology tests diagnose epidermolysis bullosa acquisita, including biopsies, DIF, salt-split skin, COL7 antibodies, and what ELISA results mean.

04

Treatment Options and Monitoring

Learn about epidermolysis bullosa acquisita (EBA) treatment, from wound care and steroids to rituximab, IVIG, medication monitoring, and specialist follow-up.

05

Assembling Your Care Team and First Visit Prep

Learn how to prepare for an epidermolysis bullosa acquisita specialist visit, organize biopsy and blood-test records, choose a care team, and plan questions.

06

Daily Management and Living with EBA

Learn how to live with epidermolysis bullosa acquisita (EBA), protect fragile skin, care for wounds, reduce itching, and manage swallowing and nutrition safely.

Common questions in this guide

What causes epidermolysis bullosa acquisita?
Epidermolysis bullosa acquisita is an autoimmune condition: the immune system mistakenly attacks type VII collagen, a protein that helps anchor the outer and inner layers of skin. The damage makes skin fragile and can cause blisters; unlike inherited epidermolysis bullosa, EBA usually begins in adulthood.
How do doctors confirm EBA?
Doctors combine your symptoms and examination with a skin biopsy and specialized immune testing. Direct immunofluorescence looks for a characteristic u-serrated pattern, while an ELISA blood test checks for antibodies against type VII collagen. A negative blood test does not completely rule out EBA, so results must be interpreted together.
What is the difference between the two main types of EBA?
The mechanobullous form causes very fragile skin and blisters after minor rubbing or bumps, often on the hands, feet, elbows, and knees; healing may leave scars or tiny white bumps called milia. The inflammatory form causes more widespread, itchy blisters and can resemble other blistering diseases. Some people may have features of both patterns.
Can EBA damage the eyes, mouth, or throat?
Yes. Blistering and scarring of mucous membranes can affect the eyes, mouth, and throat, potentially causing vision loss, trouble swallowing, or breathing problems. Your care team may recommend baseline evaluation by an ophthalmologist or gastroenterologist, even before symptoms appear, depending on your risks.
How is epidermolysis bullosa acquisita treated?
Treatment is tailored to the type and severity of EBA. Protecting the skin from friction is important, and medicines may include dapsone; more severe disease may require specialist-directed treatments such as rituximab or intravenous immunoglobulin (IVIG). Reaching remission can take many months of consistent care.
How can I prevent new EBA blisters at home?
Avoid friction and trauma by choosing soft fabrics, padded footwear, and non-adherent dressings that do not stick to the skin. Check your skin regularly for possible infection, such as increased warmth, pus, or spreading redness, and report concerning changes to your clinician.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on Epidermolysis bullosa acquisita.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my biopsy and blood work, do you consider my diagnosis of EBA to be confirmed, or are more specialized tests needed?
  2. 2.Do I have the mechanobullous form, the inflammatory form, or a combination of both?
  3. 3.Given the risk of scarring, should I be evaluated by an ophthalmologist or a gastroenterologist even if I don't have eye or throat symptoms yet?
  4. 4.What is our strategy for minimizing my long-term exposure to systemic steroids?
  5. 5.Are there any clinical trials or newer biologic therapies we should consider if my current treatment isn't effective?

References

References (14)
  1. 1

    Clinical features and diagnosis of epidermolysis bullosa acquisita.

    Vorobyev A, Ludwig RJ, Schmidt E

    Expert review of clinical immunology 2017; (13(2)):157-169 doi:10.1080/1744666X.2016.1221343.

    PMID: 27580464
  2. 2

    Propranolol Off-Target: A New Therapeutic Option in Neutrophil-Dependent Dermatoses?

    Maglie R, Solimani F, Quintarelli L, Hertl M

    The Journal of investigative dermatology 2020; (140(12)):2326-2329 doi:10.1016/j.jid.2020.06.002.

    PMID: 33222759
  3. 3

    [Epidermolysis bullosa acquisita].

    Hofmann SC, Weidinger A

    Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete 2019; (70(4)):265-270 doi:10.1007/s00105-019-4387-7.

    PMID: 30887080
  4. 4

    Epidermolysis Bullosa Acquisita-Current and Emerging Treatments.

    Tešanović Perković D, Bukvić Mokos Z, Marinović B

    Journal of clinical medicine 2023; (12(3)) doi:10.3390/jcm12031139.

    PMID: 36769788
  5. 5

    Epidermolysis Bullosa Acquisita: From Pathophysiology to Novel Therapeutic Options.

    Kasperkiewicz M, Sadik CD, Bieber K, et al.

    The Journal of investigative dermatology 2016; (136(1)):24-33 doi:10.1038/JID.2015.356.

    PMID: 26763420
  6. 6

    International Bullous Diseases Group: consensus on diagnostic criteria for epidermolysis bullosa acquisita.

    Prost-Squarcioni C, Caux F, Schmidt E, et al.

    The British journal of dermatology 2018; (179(1)):30-41 doi:10.1111/bjd.16138.

    PMID: 29165796
  7. 7

    Serological diagnostics in the detection of IgG autoantibodies against human collagen VII in epidermolysis bullosa acquisita: a multicentre analysis.

    Schmidt T, Hoch M, Lotfi Jad SS, et al.

    The British journal of dermatology 2017; (177(6)):1683-1692 doi:10.1111/bjd.15800.

    PMID: 28703393
  8. 8

    Epidermolysis bullosa acquisita.

    Miyamoto D, Gordilho JO, Santi CG, Porro AM

    Anais brasileiros de dermatologia 2022; (97(4)):409-423 doi:10.1016/j.abd.2021.09.010.

    PMID: 35701269
  9. 9

    Liver Transplant in a Patient With Acquired Epidermolysis Bullosa and Associated End-Stage Liver Disease.

    Vennarecci G, Miglioresi L, Guglielmo N, et al.

    Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation 2017; (15(3)):366-368 doi:10.6002/ect.2015.0018.

    PMID: 26671706
  10. 10

    Epidermolysis Bullosa Acquisita: A Case Report.

    Kumetz EA, Meyerle JH, Rivard SC

    The American journal of case reports 2020; (21()):e919432 doi:10.12659/AJCR.919432.

    PMID: 32310912
  11. 11

    Discrepancies in the evaluation of incapacity for work in a patient with epidermolysis bullosa acquisita between public pension fund and occupational medicine expert raise the issue of competencies.

    Lalić H

    Arhiv za higijenu rada i toksikologiju 2018; (69(1)):77-80.

    PMID: 29604201
  12. 12

    Consensus on the treatment of autoimmune bullous dermatoses: bullous pemphigoid, mucous membrane pemphigoid and epidermolysis bullosa acquisita - Brazilian Society of Dermatology.

    Santi CG, Gripp AC, Roselino AM, et al.

    Anais brasileiros de dermatologia 2019; (94(2 Suppl 1)):33-47 doi:10.1590/abd1806-4841.2019940207.

    PMID: 31166405
  13. 13

    Rituximab in the Treatment of Epidermolysis Bullosa Acquisita: A Systematic Review.

    Kianfar N, Dasdar S, Marashi A, et al.

    The Journal of clinical and aesthetic dermatology 2024; (17(7)):24-36.

    PMID: 39006807
  14. 14

    Inhibition of interferon gamma impairs induction of experimental epidermolysis bullosa acquisita.

    Gross N, Marketon J, Mousavi S, et al.

    Frontiers in immunology 2024; (15()):1343299 doi:10.3389/fimmu.2024.1343299.

    PMID: 38799441

This page explains epidermolysis bullosa acquisita for educational purposes and is not medical advice. Your dermatologist and other specialists should interpret your test results and treatment needs.